Premium Nahrungsergänzungsmittel | artgerecht

ALK – Anaplastic Lymphoma Kinase Explained

ALK (Anaplastic Lymphoma Kinase) is a gene and protein that becomes abnormally activated in certain cancers, making it a key biomarker and therapeutic target in oncology.

Regular tips about health Regular tips about health

Things worth knowing about "ALK"

ALK (Anaplastic Lymphoma Kinase) is a gene and protein that becomes abnormally activated in certain cancers, making it a key biomarker and therapeutic target in oncology.

What is ALK?

ALK stands for Anaplastic Lymphoma Kinase. It is a protein encoded by the ALK gene and belongs to the receptor tyrosine kinase family. Tyrosine kinases are enzymes that transmit signals regulating cell growth, division, and survival – processes that are tightly controlled in healthy tissue.

Under normal physiological conditions, ALK is primarily active during early embryonic development, particularly in the formation of the nervous system. In healthy adult tissue, ALK expression is very low and largely limited to certain areas of the brain.

Relevance in Oncology

ALK becomes clinically significant when genetic alterations – such as ALK gene fusions, mutations, or amplifications – lead to abnormal, constitutive activation of the ALK protein. This drives uncontrolled cell proliferation and tumor development.

Key cancer types associated with ALK alterations include:

Non-small cell lung cancer (NSCLC): Approximately 3–5% of NSCLC patients harbor an ALK gene rearrangement, most commonly the EML4-ALK fusion. This group represents one of the most important subgroups in precision oncology.
Anaplastic large cell lymphoma (ALCL): ALK rearrangements were first identified in this lymphoma subtype. ALK-positive ALCL is especially common in children and adolescents and generally carries a more favorable prognosis.
Neuroblastoma: A childhood cancer of the sympathetic nervous system in which ALK mutations are frequently detected, including inherited (germline) mutations.
Other tumors: ALK alterations have also been described in inflammatory myofibroblastic tumors, certain thyroid cancers, and colorectal cancers, among others.

Diagnosis and Testing

Identifying ALK positivity in tumor tissue is essential for treatment planning. Several diagnostic methods are available:

Fluorescence in situ hybridization (FISH): The gold standard for detecting ALK gene rearrangements in tumor tissue.
Immunohistochemistry (IHC): Detects ALK protein overexpression and is commonly used as an initial screening tool.
Next-generation sequencing (NGS): A comprehensive molecular profiling approach that can simultaneously detect ALK fusions, mutations, and other genomic alterations.
Reverse transcriptase PCR (RT-PCR): A molecular method for detecting specific ALK fusion transcripts at the RNA level.

Treatment: ALK Inhibitors

The discovery of ALK as a druggable target has transformed the treatment of ALK-positive cancers. ALK inhibitors (also called ALK tyrosine kinase inhibitors) are small molecules that selectively block the activity of the aberrant ALK protein, thereby inhibiting tumor growth.

Approved ALK Inhibitors (Selection)

Crizotinib (1st generation): The first approved ALK inhibitor; also active against MET and ROS1 alterations.
Ceritinib, Alectinib, Brigatinib (2nd generation): More potent and selective; effective against brain metastases and crizotinib-resistant tumors.
Lorlatinib (3rd generation): The most selective and broadly active ALK inhibitor to date, with excellent central nervous system (CNS) penetration and the ability to overcome most resistance mutations.

The choice of ALK inhibitor depends on the stage of disease, the presence of brain metastases, and the specific resistance mechanism identified upon disease progression.

Resistance and Next Steps

As with many targeted therapies, resistance to ALK inhibitors can develop over time. Common mechanisms include secondary mutations within the ALK kinase domain or activation of bypass signaling pathways. Repeat tissue biopsy or liquid biopsy (analysis of circulating tumor DNA) can help characterize the resistance mechanism and guide subsequent treatment decisions.

References

Soda M. et al. - Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007; 448(7153):561-566.
Hallberg B., Palmer R.H. - Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer, 2013; 13(10):685-700.
National Cancer Institute (NCI) - ALK Gene Rearrangement in Lung Cancer. www.cancer.gov (accessed 2024).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.